Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
ER - Record first-quarter revenue of €239 million, reflecting 14% topline growth .pdf

Company: Fagron N.V. Date: 2025-04-10 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
![](_page_0_Picture_1.jpeg)

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET

# **Record first-quarter revenue of €239 million, reflecting 14% topline growth**

Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2025.

# **Key Highlights**

- **Revenue maintained its strong growth momentum, increasing 14.1% on reported basis to €238.7 million (15.2% at CER), with all regions and segments contributing**
- **Organic growth at CER of 12.6% reflects strong performance in North America, and an exceptional performance in Latin America**
- **Global operational excellence initiatives on track and yielding efficiencies**
- **CareFirst acquisition closed in addition to EuroOTC and Guinama. Integration of all transactions progressing as planned and we remain committed to disciplined acquisition strategy**
- **In March 2025, FDA confirmed corrective actions at the Wichita facility adequately address requirements, pending site visit**
- **FY 2025 guidance reaffirmed: mid- to high-single digit organic sales growth at CER and slight improvement in profitability**

#### **Rafael Padilla, CEO of Fagron:**

*"I am pleased to report a strong start to 2025 with all regions contributing to another quarter of outstanding performance.*

*Our organic growth reflects the strength of our commercial strategy, continued operational efficiencies, and the successful execution of our global excellence initiatives. North America delivered another remarkable performance, supported by robust underlying trends at Compounding Services. In Latin America, growth has accelerated this quarter driven by the solid performance of Brands and Essentials. In EMEA, performance improved through the quarter more than offsetting the tough comparison against a strong Q1 2024.* 

*We continue to demonstrate the strength of our business model and value proposition driven by a culture of quality and innovation, which positions Fagron to lead the pharmaceutical compounding industry. In this regard, I am pleased to share that FDA has acknowledged our corrective actions in Wichita adequately addressed their requirements, pending a site visit. This highlights our efforts and strong commitment to quality, a key differentiator and enabler of long-term value creation.*

*We have just closed our third transaction in 2025, by completing the acquisition of CareFirst, which will reinforce Anazao's footprint with a third facility in the North-East of the country. We are on track with the integration of all our recent acquisitions and remain committed to exploring market opportunities globally that will further strengthen our position.*

*Looking ahead, we remain confident in our outlook and reiterate our full year 2025 guidance, as we continue to capitalize on growth opportunities that support our strategic objectives.*"

![](_page_1_Figure_0.jpeg)

# **Key Financial Figures**

#### **Q1 2025**

| (€ '000)      | Revenue per region |         |       |       |              |                  |
|---------------|--------------------|---------|-------|-------|--------------|------------------|
|               | Q1 '25             | Q1 '24  | ∆     | ∆ CER | ∆<br>Organic | ∆ Organic<br>CER |
| EMEA          | 87,899             | 79,590  | 10.4% | 9.8%  | 4.0%         | 3.4%             |
| Latin America | 42,458             | 41,358  | 2.7%  | 17.7% | 2.7%         | 17.7%            |
| North America | 108,369            | 88,282  | 22.8% | 19.0% | 22.2%        | 18.4%            |
| Group         | 238,726            | 209,230 | 14.1% | 15.2% | 11.4%        | 12.6%            |

|                              | Revenue per segment |        |       |       |              |                  |
|------------------------------|---------------------|--------|-------|-------|--------------|------------------|
| (€ '000)                     | Q1 '25              | Q1 '24 | ∆     | ∆ CER | ∆<br>Organic | ∆ Organic<br>CER |
| Essentials                   | 94,471              | 83,537 | 13.1% | 16.8% | 8.7%         | 12.4%            |
| Brands                       | 34,280              | 32,061 | 6.9%  | 13.2% | 6.0%         | 12.3%            |
| Compounding<br>Services (CS) | 109,976             | 93,632 | 17.5% | 14.6% | 15.7%        | 12.8%            |

#### **Outlook**

Assuming no significant changes in current market conditions, we expect mid- to high-single digit organic revenue growth at CER and slight improvement in profitability YoY (H2 higher than H1). Capex to remain at around 3.5% of revenue during FY 2025 (excluding one-off capex).

Please refer to today's CMD press release for the updated mid-term guidance.

We remain committed to our disciplined acquisition strategy globally as part of Fagron's growth strategy.

#### **Regional highlights**

#### EMEA

| (€ '000)      | Q1 '25 | Q1 '24 | ∆     | ∆ CER | ∆<br>Organic | ∆ Organic<br>CER |
|---------------|--------|--------|-------|-------|--------------|------------------|
| Essentials    | 45,547 | 40,677 | 12.0% | 11.5% | 2.9%         | 2.5%             |
| Brands        | 13,720 | 12,269 | 11.8% | 11.5% | 9.4%         | 9.0%             |
| CS            | 28,632 | 26,644 | 7.5%  | 6.5%  | 3.2%         | 2.3%             |
| Total revenue | 87,899 | 79,590 | 10.4% | 9.8%  | 4.0%         | 3.4%             |

• Revenue development in the EMEA region was driven by a resilient performance from all businesses, supported by the incremental contribution from M&A.

- Brands and Essentials growth was driven by Global Brands underpinning our innovation power, while Essentials performance reflects tough comparison against the first quarter of 2024.
- Compounding Services benefitted from robust demand and drug shortages.
- During the quarter, EuroOTC and Guinama transactions were closed and, along with LSP and Parma Produkt, we continue making progress on all recent integrations.

![](_page_2_Figure_0.jpeg)

### Latin America

| (€ '000)      | Q1 '25 | Q1 '24 | ∆      | ∆ CER | ∆<br>Organic | ∆ Organic<br>CER |
|---------------|--------|--------|--------|-------|--------------|------------------|
| Essentials    | 26,270 | 26,418 | -0.6%  | 14.4% | -0.6%        | 14.4%            |
| Brands        | 15,213 | 13,854 | 9.8%   | 25.9% | 9.8%         | 25.9%            |
| CS            | 975    | 1,086  | -10.2% | -7.0% | -10.2%       | -7.0%            |
| Total revenue | 42,458 | 41,358 | 2.7%   | 17.7% | 2.7%         | 17.7%            |

- Revenue development in Latin America was accelerated by the strong underlying growth in Brands and Essentials and the timing of the Easter holidays.
- Essentials revenue development maintained its momentum, supported by industry sales and selective recovery in top-selling ingredients. Brands saw outstanding growth by leveraging our broad product portfolio, new product launches, and better product availability. As a result, Brands accounted for 36.7% of the total B&E revenue in Latin America (+230bps from Q1 2024).
- Compounding Services (Colombia) reflects the healthcare system changes that are affecting buying behaviors amongst clients.
- We remain in the process of closing our two signed acquisitions in this region, namely, Purifarma and Injeplast.

| (€ '000)      | Q1 '25  | Q1 '24 | ∆      | ∆ CER  | ∆<br>Organic | ∆ Organic<br>CER |
|---------------|---------|--------|--------|--------|--------------|------------------|
| Essentials    | 22,654  | 16,442 | 37.8%  | 33.5%  | 37.8%        | 33.5%            |
| Brands        | 5,347   | 5,939  | -10.0% | -12.7% | -10.0%       | -12.7%           |
| CS            | 80,368  | 65,902 | 22.0%  | 18.2%  | 21.2%        | 17.4%            |
| Total revenue | 108,369 | 88,282 | 22.8%  | 19.0%  | 22.2%        | 18.4%            |

#### North America

- Revenue growth in North America was driven by continued exceptional performance at Compounding Services and Brands & Essentials.
- Despite a challenged performance at Brands this quarter, B&E revenue continued its healthy quarterly developments, and also benefitted from the impact of drug shortages in this quarter.
- Compounding Services continued its strong growth driven by portfolio expansion within the existing customer base, onboarding new customers and drug shortages. At the end of the quarter, the Boston facility was able to ship to 47 states.
- We closed the acquisition of CareFirst at the end of March and now focus on its timely integration. In March 2025, we received an official communication from the FDA confirming that our corrective actions meet their requirements, pending a site visit, after the warning letter we received in December 2024 about our Wichita facility.

#### **Webcast**

We invite you to join our Capital Markets Day, today at 2.00 PM CET via this [link.](https://edge.media-server.com/mmc/p/pnq5qcga)

As we will be hosting our Capital Markets Day today, we will not be holding a Q1 2025 results call. However, a Q1 2025 presentation will be available to download from the Fagron [website](https://investors.fagron.com/) around 12.00 PM CET.

![](_page_3_Figure_0.jpeg)

# **Financial calendar 2025**

| 10 April 2024  | Capital Markets Day 2025          |
|----------------|-----------------------------------|
| 12 May 2025    | Annual General Meeting 2024       |
| 31 July 2025   | Half year results 2025            |
| 9 October 2025 | Trading update third quarter 2025 |

## **Further information**

Ignacio Artola Global Investor Relations Leader Tel. +34 670385795 [ignacio.artola@fagron.com](mailto:ignacio.artola@fagron.com)

#### **About Fagron**

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

#### **Important information regarding forward-looking statements**

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

*In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.*